Navigation Links
Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006

found in note 1(b) to the December 31, 2007 audited consolidated financial statements. Amounts, unless specified otherwise, are expressed in U.S. dollars. Financial results are reported under U.S. generally accepted accounting principles. All per share amounts are stated on a diluted basis unless otherwise noted.




(in thousands of

U.S.$, except

per share data) December 31, 2007 December 31, 2006


Reported As Pre-

(Prelim- Adjust- viously Restate- As

inary) ments Revised Reported ments Restated


Statement of




License and

royalty fees 18,652 - 18,652 25,605 381 a. 25,986

Cost of


sold 95,529 (580) b. 94,949 68,067 1,476 b. 69,543





tive 99,713 (398) c. 99,315 78,732 201 c. 78,933



income (21,717) 978 (20,739) 60,222 (2,058) 58,164

Income (loss)





income taxes



effect of

change in

accounting (71,570) 978 (70,592) 22,173 (2,058) 20,115

Income tax


(recovery) (23,608) 9,063 d. (14,545) 10,279 (8,187) d. 2,092

Net loss from



net of taxes (11,395) 1,502 e. (9,893) (7,708) - (7,708)

Net (loss)

income for

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Angiotech and Rex Medical announce exclusive licensing and distribution agreement for the "Option(TM)" inferior vena cava filter
2. Angiotech showcases its Hemostream(TM) Dialysis Catheter at the Society of Interventional Radiology (SIR) Annual Meeting
3. Angiotech announces results for the fourth quarter ended December 31, 2007
4. Angiotech to participate in Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
5. Angiotech Pharmaceuticals, Inc. - Notice of Conference Call and Webcast
6. Angiotech and Symphony Medical Announce Licensing Agreement
7. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
8. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech to participate in Bank of America 2007 Credit Conference
11. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
Post Your Comments:
(Date:7/25/2014)... York (PRWEB) July 25, 2014 According ... Research, "Biological Drugs Market - Global Industry Analysis, Size, ... global biological drugs market is estimated at USD 161,056.5 ... a CAGR of 10.1% from 2014 to 2020, to ... 2020. , The biological drugs market is witnessing a ...
(Date:7/25/2014)... The Conferee Networking committee is pleased to ... These two-hour sessions provide a unique networking opportunity for ... discuss new techniques, or brainstorm new ideas in an ... for consideration is August 31, 2014, and instructions can ... committee will review the topics, and status notifications will ...
(Date:7/25/2014)... , July 25, 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: ... focused on the development and commercialization of a once-daily, ... cholesterol gallstones, today announced financial results for the period ... Financial Summary: , Reported cash and cash equivalents ... $137,000 at December 31, 2013.  , Reported a ...
(Date:7/25/2014)... July 25, 2014 At the request ... granted a 60-day extension for the public comment period ... Rule for Model Aircraft established by Congress as part ... The 60-day extension establishes the new deadline for comments ... Department of Transportation/FAA notice published in the Federal Register ...
Breaking Biology Technology:Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Pittcon 2015 Announces Call for Topics for Conferee Networking Sessions 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6FAA Grants Comment Extension at the Request of AMA 2
... Biopharmaceuticals,Inc. (Nasdaq: KERX ) will hold a conference ... to discuss the Third Quarter 2007 financial results.,Michael S. ... will,host the call. Keryx will announce its financial results ... prior to the call. In order to participate ...
... Positive Phase I Results for R1507, COPENHAGEN, October ... from a Phase I study of R1507 in patients,with ... a human,monoclonal antibody targeting the insulin-like growth factor receptor,(IGF-1R) ... Nine of 34 adult patients with solid tumors experienced ...
... Calif., Oct. 23 InVitria has released ... factor for cell culture,media outperforms transferrin and ... Because Lacromin is produced in a completely,animal-free ... over,animal-derived alternatives including bovine and human transferrin. ...
Cached Biology Technology:Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT 2Phase I Results Announced for R1507 From Genmab's Collaboration With Roche 2Phase I Results Announced for R1507 From Genmab's Collaboration With Roche 3InVitria's Animal Free Lacromin(TM) Provides a Cost-Effective Improvement Over Transferrin 2
(Date:7/25/2014)... consume the healthcare community and remain priority ... To address the worldwide crisis of obesity ... global leaders in diabetes, epidemiology and public ... and development of diverse intervention programs in ... This book on "Global Health Perspectives in ...
(Date:7/25/2014)... diffusion tensor tractography (DTT), which is derived from ... for three motor tracts, such as the corticospinal ... became possible. The corticospinal tract is known to ... in the human brain. Several studies have reported ... herniation. In addition, some studies have demonstrated recovery ...
(Date:7/25/2014)... have detected an unknown interaction between microorganisms and salt. ... a droplet of salt water and is left to ... biomineralogical biosaline 3D morphologically complex formations, where they hibernate. ... The discovery was made by chance with a home ... Astrobiology journal and may help to find signs ...
Breaking Biology News(10 mins):What constitutes an effective response to the global 'diabesity' tsunami? 2Bacteria manipulate salt to build shelters to hibernate 2
... 2, 2014 EcoHealth Alliance, a nonprofit organization ... issues, and Bat Conservation International, which works to ... are joining forces in formal partnership. The organizations ... and public health programs that enhance outreach with ...
... N.C. A new Duke University-led study has documented dramatic, ... estuary. "The natural short-term variability in acidity ... global predictions for the ocean as a whole and may ... organisms, particularly shelled organisms that are especially susceptible to changes ...
... centuries as a pain reliever in Chinese medicine may be ... chronic pain. A key pain-relieving ingredient is a compound known ... plant Corydalis , a member of the poppy family, ... Press journal Current Biology on January 2. ...
Cached Biology News:EcoHealth Alliance and Bat Conservation International forge partnership to work on global bat conservation and public health issues 2Local factors cause dramatic spikes in coastal ocean acidity 2Plant used in Chinese medicine fights chronic pain 2
Request Info...
LECHNER AND LaVECK MEDIUMfor the clonal growth of normal human bronchial and other epithelial cells. Requires additives. With glutamine.Recommended storage condition:oC to 8oCIntended use(s):research...
The FliTrx Panning Kit is designed to simplify panning for protein-protein interactions with the FliTrx Random Peptide Display Library or the pFliTrx Peptide Display Vector....
Biology Products: